Compare · HROW vs NVO
HROW vs NVO
Side-by-side comparison of Harrow Inc. (HROW) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both HROW and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $183.15B, about 148.4x HROW ($1.23B).
- Over the past year, HROW is up 9.6% and NVO is down 45.7% - HROW leads by 55.3 points.
- NVO has been more active in the news (8 items in the past 4 weeks vs 5 for HROW).
- NVO has more recent analyst coverage (25 ratings vs 10 for HROW).
- Company
- Harrow Inc.
- Novo Nordisk A/S
- Price
- $33.11-0.21%
- $41.01-4.51%
- Market cap
- $1.23B
- $183.15B
- 1M return
- -15.23%
- -10.44%
- 1Y return
- +9.64%
- -45.66%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 5
- 8
- Recent ratings
- 10
- 25
Harrow Inc.
Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and Visionology, a membership-based online eye health and medication platform. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc., a commercial-stage pharmaceutical company that engages in developing and commercializing drug products. Harrow Health, Inc. owns royalty rights in four clinical stage drug candidates being developed by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was founded in 1998 and is headquartered in San Diego, California.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest HROW
- Harrow Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Harrow to Present at William Blair's 46th Annual Growth Stock Conference
- Director Silvernail Lauren P bought $31,000 worth of shares (1,000 units at $31.00) (SEC Form 4)
- Director Graves Adrienne L bought $31,070 worth of shares (1,000 units at $31.07) (SEC Form 4)
- SEC Form 4 filed by CHIEF SCIENTIFIC OFFICER Shojaei Amir
- CHIEF EXECUTIVE OFFICER Baum Mark L bought $302,000 worth of shares (10,000 units at $30.20), increasing direct ownership by 0.33% to 2,996,130 units (SEC Form 4)
- PRESIDENT AND CFO Boll Andrew R. bought $104,650 worth of shares (3,500 units at $29.90), increasing direct ownership by 0.43% to 814,679 units (SEC Form 4)
- SEC Form 10-Q filed by Harrow Inc.
- Harrow Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- Harrow Announces First Quarter 2026 Financial Results
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care